Claudia Ulbrich (Cardior Therapeutics)
August 25, 2021 05:00 AM EDTUpdated 09:18 AM
Financing

A Bris­tol My­ers-backed biotech wants to treat heart dis­ease with non-cod­ing RNAs. It's one step clos­er to proof-of-con­cept

Max Gelman

Senior Editor

Is it pos­si­ble to use strands of non-cod­ing RNA, a bur­geon­ing ther­a­peu­tic area that re­searchers now be­lieve plays an im­por­tant part in how sim­i­lar genes …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

A service from the Financial Times